

Shree Ram Singh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/739448/publications.pdf>

Version: 2024-02-01

130
papers

3,266
citations

159585

30
h-index

214800

47
g-index

134
all docs

134
docs citations

134
times ranked

4483
citing authors

#	ARTICLE	IF	CITATIONS
1	Disruption of the lipolysis pathway results in stem cell death through a sterile immunity-like pathway in adult <i>Drosophila</i> . <i>Cell Reports</i> , 2022, 39, 110958.	6.4	2
2	Combination Methionine-methylation-axis Blockade: A Novel Approach to Target the Methionine Addiction of Cancer. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 113-120.	2.0	12
3	Patient-derived orthotopic xenograft models of sarcoma. <i>Cancer Letters</i> , 2020, 469, 332-339.	7.2	17
4	The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 285-291.	2.3	27
5	Novel targets identified by integrated cancer-stromal interactome analysis of pancreatic adenocarcinoma. <i>Cancer Letters</i> , 2020, 469, 217-227.	7.2	19
6	Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2020, 523, 135-139.	2.1	15
7	TRAF6-Mediated Inflammatory Cytokines Secretion in LPS-induced Colorectal Cancer Cells Is Regulated by miR-140. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 23-33.	2.0	8
8	PPAR α Agonist Pioglitazone in Combination With Cisplatin Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 35-40.	2.0	24
9	Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival. <i>Translational Oncology</i> , 2020, 13, 100826.	3.7	6
10	A novel patient-derived orthotopic xenograft (PDOX) mouse model of highly-aggressive liver metastasis for identification of candidate effective drug-combinations. <i>Scientific Reports</i> , 2020, 10, 20105.	3.3	8
11	Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model. <i>Cancer Letters</i> , 2020, 492, 174-184.	7.2	21
12	Ischemia reperfusion-induced metastasis is resistant to PPAR α agonist pioglitazone in a murine model of colon cancer. <i>Scientific Reports</i> , 2020, 10, 18565.	3.3	0
13	Comparison of the Efficacy of EGFR Tyrosine Kinase Inhibitors Erlotinib and Low-dose Osimertinib on a PC-9-GFP EGFR Mutant Non-small-cell Lung Cancer Growing in the Brain of Nude Mice. <i>In Vivo</i> , 2020, 34, 1027-1030.	1.3	0
14	A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 217-223.	2.0	7
15	Eribulin Regresses a Cisplatin-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model. <i>Anticancer Research</i> , 2020, 40, 2475-2479.	1.1	7
16	A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model. <i>Anticancer Research</i> , 2020, 40, 2481-2485.	1.1	6
17	Recombinant Methioninase Combined With Tumor-targeting <i>Salmonella typhimurium</i> A1-R Induced Regression in a PDOX Mouse Model of Doxorubicin-resistant Dedifferentiated Liposarcoma. <i>Anticancer Research</i> , 2020, 40, 2515-2523.	1.1	4
18	Temozolomide and Pazopanib Combined with FOLFOX Regressed a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model. <i>Translational Oncology</i> , 2020, 13, 100739.	3.7	4

#	ARTICLE	IF	CITATIONS
19	Pazopanib Inhibits Tumor Growth, Lymph-node Metastasis and Lymphangiogenesis of an Orthotopic Mouse of Colorectal Cancer. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 131-139.	2.0	9
20	Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 351-358.	2.0	3
21	Exquisite Tumor Targeting by Salmonella A1-R in Combination with Caffeine and Valproic Acid Regresses an Adult Pleomorphic Rhabdomyosarcoma Patient-Derived Orthotopic Xenograft Mouse Model. <i>Translational Oncology</i> , 2020, 13, 393-400.	3.7	7
22	Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models. <i>Journal of Drug Targeting</i> , 2019, 27, 211-216.	4.4	11
23	A pharmacogenomic analysis using L1000CDS2 identifies BX-795 as a potential anticancer drug for primary pancreatic ductal adenocarcinoma cells. <i>Cancer Letters</i> , 2019, 465, 82-93.	7.2	13
24	Sorafenib and Palbociclib Combination Regresses a Cisplatin-resistant Osteosarcoma in a PDOX Mouse Model. <i>Anticancer Research</i> , 2019, 39, 4079-4084.	1.1	24
25	Tumor-sealing Surgical Orthotopic Implantation of Human Colon Cancer in Nude Mice Induces Clinically-relevant Metastases Without Early Peritoneal Carcinomatosis. <i>Anticancer Research</i> , 2019, 39, 4065-4071.	1.1	6
26	The Combination of Olaratumab with Doxorubicin and Cisplatin Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model. <i>Translational Oncology</i> , 2019, 12, 1257-1263.	3.7	18
27	Hair-follicle-associated pluripotent stem cells derived from cryopreserved intact human hair follicles sustain multilineage differentiation potential. <i>Scientific Reports</i> , 2019, 9, 9326.	3.3	18
28	Peritoneal Metastases in a Patient-derived Orthotopic Xenograft (PDOX) Model of Colon Cancer Imaged Non-invasively via Red Fluorescent Protein Labeled Stromal Cells. <i>Anticancer Research</i> , 2019, 39, 3463-3467.	1.1	8
29	Oral recombinant methioninase combined with oxaliplatin and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2019, 61, 109-114.	2.2	17
30	Eribulin Suppressed Cisplatin- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. <i>Anticancer Research</i> , 2019, 39, 4775-4779.	1.1	16
31	Combination of Trabectedin With Oxaliplatin and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model. <i>Anticancer Research</i> , 2019, 39, 5999-6005.	1.1	4
32	Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatin in a Patient-derived Orthotopic Xenograft Mouse Model. <i>Anticancer Research</i> , 2019, 39, 4667-4671.	1.1	26
33	MyD88 Regulates LPS-induced NF- κ B/MAPK Cytokines and Promotes Inflammation and Malignancy in Colorectal Cancer Cells. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 409-419.	2.0	20
34	Efficacy of oral recombinant methioninase combined with oxaliplatin and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2019, 518, 306-310.	2.1	29
35	Pioglitazone, an agonist of PPAR γ , reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109356.	5.6	28
36	Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model. <i>Anticancer Research</i> , 2019, 39, 4781-4786.	1.1	22

#	ARTICLE	IF	CITATIONS
37	Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy. <i>Anticancer Research</i> , 2019, 39, 5339-5344.	1.1	6
38	Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model. <i>Biochemical and Biophysical Research Communications</i> , 2019, 509, 1041-1046.	2.1	12
39	Expression of anti-aging type-XVII collagen (COL17A1/BP180) in hair follicle-associated pluripotent (HAP) stem cells during differentiation. <i>Tissue and Cell</i> , 2019, 59, 33-38.	2.2	12
40	The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model. <i>Biomedicine and Pharmacotherapy</i> , 2019, 117, 109093.	5.6	4
41	Pazopanib regresses a doxorubicin-resistant synovial sarcoma in a patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2019, 58, 107-111.	2.2	3
42	Temozolomide targets and arrests a doxorubicin-resistant follicular dendritic-cell sarcoma patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2019, 58, 17-23.	2.2	10
43	Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model. <i>Cancer Letters</i> , 2019, 451, 122-127.	7.2	11
44	Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 809-815.	2.3	16
45	Trabectedin and irinotecan combination regresses a cisplatin-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2019, 513, 326-331.	2.1	34
46	The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1075-1082.	2.3	7
47	Tumor-targeting <i>Salmonella typhimurium</i> A1-R overcomes nab-paclitaxel resistance in a cervical cancer PDOX mouse model. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1683-1690.	1.7	14
48	A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent leiomyosarcoma. <i>Pharmacological Research</i> , 2019, 142, 169-175.	7.1	14
49	Osimertinib Regresses an EGFR-Mutant Cisplatin-Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice. <i>Translational Oncology</i> , 2019, 12, 640-645.	3.7	10
50	Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatin, Overcome Cisplatin-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma. <i>Anticancer Research</i> , 2019, 39, 4653-4657.	1.1	30
51	Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model. <i>Anticancer Research</i> , 2019, 39, 6463-6470.	1.1	4
52	The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Biomedicine and Pharmacotherapy</i> , 2019, 111, 835-840.	5.6	10
53	Detection of Metastasis in a Patient-derived Orthotopic Xenograft (PDOX) Model of Undifferentiated Pleomorphic Sarcoma with Red Fluorescent Protein. <i>Anticancer Research</i> , 2019, 39, 81-85.	1.1	19
54	Hair-Follicle-Associated Pluripotent (HAP) Stem Cells Encapsulated on Polyvinylidene Fluoride Membranes (PFM) Promote Functional Recovery from Spinal Cord Injury. <i>Stem Cell Reviews and Reports</i> , 2019, 15, 59-66.	5.6	10

#	ARTICLE	IF	CITATIONS
55	Cancer Stem Cells and Stem Cell Tumors in Drosophila. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1167, 175-190.	1.6	7
56	Tumor-targeting <i>Salmonella typhimurium</i> A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse models. <i>Biochemical and Biophysical Research Communications</i> , 2018, 497, 1055-1061.	2.1	28
57	Novel cancer gene variants and gene fusions of triple-negative breast cancers (TNBCs) reveal their molecular diversity conserved in the patient-derived xenograft (PDX) model. <i>Cancer Letters</i> , 2018, 428, 127-138.	7.2	19
58	Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. <i>Cancer Letters</i> , 2018, 417, 168-173.	7.2	56
59	Combining Tumor-Selective Bacterial Therapy with <i>Salmonella typhimurium</i> A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model. <i>Chemotherapy</i> , 2018, 63, 278-283.	1.6	25
60	Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma. <i>Biochemical and Biophysical Research Communications</i> , 2018, 506, 912-917.	2.1	29
61	Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model. <i>Anticancer Research</i> , 2018, 38, 5639-5644.	1.1	50
62	A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting <i>Salmonella typhimurium</i> A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2018, 505, 733-739.	2.1	18
63	Tumor-targeting <i>Salmonella typhimurium</i> A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP). <i>Tissue and Cell</i> , 2018, 54, 144-149.	2.2	8
64	Markers and Methods to Study Adult Midgut Stem Cells. <i>Methods in Molecular Biology</i> , 2018, 1842, 123-137.	0.9	3
65	Combination therapy of tumor-targeting <i>Salmonella typhimurium</i> A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 3086-3092.	2.1	27
66	MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. <i>Tissue and Cell</i> , 2018, 52, 124-128.	2.2	19
67	The Emerging Roles of microRNAs in Stem Cell Aging. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1056, 11-26.	1.6	10
68	Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting <i>S. typhimurium</i> A1-R is superior to first-line chemotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 12.	17.1	5
69	Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2018, 53, 30-36.	2.2	18
70	Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>BMC Cancer</i> , 2018, 18, 840.	2.6	14
71	Tumor-targeting <i>Salmonella typhimurium</i> A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations. <i>Heliyon</i> , 2018, 4, e00643.	3.2	11
72	Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. <i>Cancer Letters</i> , 2018, 432, 251-259.	7.2	59

#	ARTICLE	IF	CITATIONS
73	Circulating Endothelial Progenitor Cells in Crohn's Disease: An EPC in the Making?. Digestive Diseases and Sciences, 2017, 62, 567-568.	2.3	3
74	Stem-Cell-Based Tumorigenesis in Adult Drosophila. Current Topics in Developmental Biology, 2017, 121, 311-337.	2.2	13
75	Birt-Hogg-Dubé Syndrome. , 2017, , 514-518.		0
76	Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature. Oncotarget, 2016, 7, 62533-62546.	1.8	46
77	Targeting tumor microenvironment in cancer therapy. Cancer Letters, 2016, 380, 203-204.	7.2	39
78	Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells by elevated ROS production. Cancer Letters, 2016, 382, 157-165.	7.2	33
79	The lipolysis pathway sustains normal and transformed stem cells in adult Drosophila. Nature, 2016, 538, 109-113.	27.8	77
80	Whole-animal genome-wide RNAi screen identifies networks regulating male germline stem cells in Drosophila. Nature Communications, 2016, 7, 12149.	12.8	22
81	Featuring the guest editors: Special issue tumor microenvironment. Cancer Letters, 2016, 380, 201-202.	7.2	0
82	Complement proteins C7 and CFH control the stemness of liver cancer cells via LSF-1. Cancer Letters, 2016, 372, 24-35.	7.2	48
83	The novel tumour suppressor Madm regulates stem cell competition in the Drosophila testis. Nature Communications, 2016, 7, 10473.	12.8	34
84	The Nuclear Matrix Protein Megator Regulates Stem Cell Asymmetric Division through the Mitotic Checkpoint Complex in Drosophila Testes. PLoS Genetics, 2015, 11, e1005750.	3.5	7
85	Curcumin inhibits PhIP induced cytotoxicity in breast epithelial cells through multiple molecular targets. Cancer Letters, 2015, 365, 122-131.	7.2	44
86	Genome-wide RNAi Screen Identifies Networks Involved in Intestinal Stem Cell Regulation in Drosophila. Cell Reports, 2015, 10, 1226-1238.	6.4	88
87	Cartilage Regeneration of Adipose-Derived Stem Cells in the TGF- β 1-Immobilized PLGA-Gelatin Scaffold. Stem Cell Reviews and Reports, 2015, 11, 453-459.	5.6	40
88	Integrated genomic analyses identify KDM1A's role in cell proliferation via modulating E2F signaling activity and associate with poor clinical outcome in oral cancer. Cancer Letters, 2015, 367, 162-172.	7.2	17
89	Bioinformatic and metabolomic analysis reveals miR-155 regulates thiamine level in breast cancer. Cancer Letters, 2015, 357, 488-497.	7.2	36
90	Cancer Metabolism: Targeting metabolic pathways in cancer therapy. Cancer Letters, 2015, 356, 147-148.	7.2	12

#	ARTICLE	IF	CITATIONS
91	Hypoxia and hypoxia inducible factors in tumor metabolism. <i>Cancer Letters</i> , 2015, 356, 263-267.	7.2	129
92	Featuring the guest editor: Special issue cancer metabolism. <i>Cancer Letters</i> , 2015, 356, 145-146.	7.2	0
93	The emerging roles of microRNAs in cancer metabolism. <i>Cancer Letters</i> , 2015, 356, 301-308.	7.2	97
94	Epigenetic silencing of microRNA-373 to epithelial-mesenchymal transition in non-small cell lung cancer through IRAK2 and LAMP1 axes. <i>Cancer Letters</i> , 2014, 353, 232-241.	7.2	61
95	Development and characterization of a colon PDX model that reproduces drug responsiveness and the mutation profiles of its original tumor. <i>Cancer Letters</i> , 2014, 345, 56-64.	7.2	41
96	Role of MicroRNAs in Stem Cell Regulation and Tumorigenesis in <i>Drosophila</i> . , 2014, , 69-80.		1
97	Generating Double Knockout Mice to Model Genetic Intervention for Diabetic Cardiomyopathy in Humans. <i>Methods in Molecular Biology</i> , 2014, 1194, 385-400.	0.9	10
98	Featuring the special issue guest editor: Shree Ram Singh, Ph.D.. <i>Cancer Letters</i> , 2013, 338, 3.	7.2	0
99	Cancer stem cells: Recent developments and future prospects. <i>Cancer Letters</i> , 2013, 338, 1-2.	7.2	17
100	Gastric cancer stem cells: A novel therapeutic target. <i>Cancer Letters</i> , 2013, 338, 110-119.	7.2	80
101	<i>Drosophila</i> Eye as a Model to Study Regulation of Growth Control: The Discovery of Size Control Pathways. , 2013, , 229-270.		1
102	Cardiac Stem Cell Niche, MMP9, and Culture and Differentiation of Embryonic Stem Cells. <i>Methods in Molecular Biology</i> , 2013, 1035, 153-163.	0.9	11
103	Genetic, Immunofluorescence Labeling, and In Situ Hybridization Techniques in Identification of Stem Cells in Male and Female Germline Niches. <i>Methods in Molecular Biology</i> , 2013, 1035, 9-23.	0.9	2
104	Editorial (Stem Cells in Regenerative Medicine and Cancer). <i>Current Medicinal Chemistry</i> , 2012, 19, 5964-5964.	2.4	0
105	Generation and Staining of Intestinal Stem Cell Lineage in Adult Midgut. <i>Methods in Molecular Biology</i> , 2012, 879, 47-69.	0.9	19
106	Stem Cell Niche in Tissue Homeostasis, Aging and Cancer. <i>Current Medicinal Chemistry</i> , 2012, 19, 5965-5974.	2.4	24
107	Stem Cell Niche in Tissue Homeostasis, Aging and Cancer. <i>Current Medicinal Chemistry</i> , 2012, 19, 5965-5974.	2.4	31
108	Chondrogenic differentiation of induced pluripotent stem cells from osteoarthritic chondrocytes in alginate matrix. , 2012, 23, 1-12.		121

#	ARTICLE	IF	CITATIONS
109	Editorial [Stem Cells in Regenerative Medicine and Cancer Guest Editor: Shree R. Singh & Werner Hoffmann]. <i>Current Medicinal Chemistry</i> , 2012, 19, 5964-5964.	2.4	0
110	Hypoxia, stem cells and bone tumor. <i>Cancer Letters</i> , 2011, 313, 129-136.	7.2	58
111	Spermatogonial stem cells, infertility and testicular cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 468-483.	3.6	68
112	The adult <i>Drosophila</i> gastric and stomach organs are maintained by a multipotent stem cell pool at the foregut/midgut junction in the cardia (proventriculus). <i>Cell Cycle</i> , 2011, 10, 1109-1120.	2.6	61
113	JAK-STAT is restrained by Notch to control cell proliferation of the <i>Drosophila</i> intestinal stem cells. <i>Journal of Cellular Biochemistry</i> , 2010, 109, 992-999.	2.6	94
114	Competitiveness for the niche and mutual dependence of the germline and somatic stem cells in the <i>Drosophila</i> testis are regulated by the JAK/STAT signaling. <i>Journal of Cellular Physiology</i> , 2010, 223, 500-510.	4.1	57
115	Tumor suppressors Sav/scrib and oncogene ras regulate stem cell transformation in adult <i>Drosophila</i> malpighian tubules. <i>Journal of Cellular Physiology</i> , 2010, 224, 766-774.	4.1	34
116	Stem cells as a therapeutic target for diabetes. <i>Frontiers in Bioscience - Landmark</i> , 2010, 15, 461.	3.0	42
117	Stem cells as potential therapeutic targets for inflammatory bowel disease. <i>Frontiers in Bioscience - Scholar</i> , 2010, S2, 993-1008.	2.1	43
118	Multipotent stem cells in the Malpighian tubules of adult <i>Drosophila melanogaster</i> . <i>Journal of Experimental Biology</i> , 2009, 212, 413-423.	1.7	34
119	Germline Stem Cells. <i>Methods in Molecular Biology</i> , 2008, 450, v.	0.9	7
120	Lessons Learned About Adult Kidney Stem Cells From the Malpighian Tubules of <i>Drosophila</i> . <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 660-666.	6.1	29
121	Immunohistological Techniques for Studying the <i>Drosophila</i> Male Germline Stem Cell. <i>Methods in Molecular Biology</i> , 2008, 450, 45-59.	0.9	14
122	The Adult <i>Drosophila</i> Malpighian Tubules Are Maintained by Multipotent Stem Cells. <i>Cell Stem Cell</i> , 2007, 1, 191-203.	11.1	173
123	Rap-GEF Signaling Controls Stem Cell Anchoring to Their Niche through Regulating DE-Cadherin-Mediated Cell Adhesion in the <i>Drosophila</i> Testis. <i>Developmental Cell</i> , 2006, 10, 117-126.	7.0	97
124	JAK/STAT signaling regulates tissue outgrowth and male germline stem cell fate in <i>Drosophila</i> . <i>Cell Research</i> , 2005, 15, 1-5.	12.0	33
125	Assortative Mating in <i>Drosophila</i> Adapted to a Microsite Ecological Gradient. <i>Behavior Genetics</i> , 2005, 35, 753-764.	2.1	27
126	Female remating, sperm competition and sexual selection in <i>Drosophila</i> . <i>Genetics and Molecular Research</i> , 2002, 1, 178-215.	0.2	57

#	ARTICLE	IF	CITATIONS
127	Female Remating in <i>Drosophila ananassae</i> : Evidence for Sperm Displacement and Greater Productivity after Remating. <i>Zoological Science</i> , 2001, 18, 181-185.	0.7	9
128	Title is missing!. <i>Journal of Insect Behavior</i> , 2001, 14, 659-668.	0.7	7
129	Male Remating in <i>Drosophila ananassae</i> : Evidence for Interstrain Variation in Remating Time and Shorter Duration of Copulation during Second Mating. <i>Zoological Science</i> , 2000, 17, 389-393.	0.7	12
130	Male Remating in <i>Drosophila ananassae</i> . Evidence for Interstrain Variation in Remating Time and Shorter Duration of Copulation during Second Mating.. <i>Zoological Science</i> , 2000, 17, 389-393.	0.7	3